Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program.
Buprenorphine
Buprenorphine waiver program
Opioid agonist treatment
Opioid use disorder
Journal
Journal of substance abuse treatment
ISSN: 1873-6483
Titre abrégé: J Subst Abuse Treat
Pays: United States
ID NLM: 8500909
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
16
11
2020
revised:
17
04
2021
accepted:
22
04
2021
pubmed:
8
6
2021
medline:
22
3
2022
entrez:
7
6
2021
Statut:
ppublish
Résumé
To evaluate associations between new types of buprenorphine waivers (nurse practitioner and physician assistant [NP/PA]; 275-patient limit [MD/DO-275]) and both buprenorphine prescribing and health outcomes. Using comprehensive county-level data from California 2010-2018, we modeled quarterly associations between numbers of NP/PA and MD/DO-275 waivers and rates of buprenorphine prescribing, opioid-related deaths, emergency department (ED) visits, and hospitalizations among all counties and separately among metropolitan and nonmetropolitan counties using Poisson regression models with county and quarter fixed effects and adjusting for time-varying covariates. Each additional NP/PA and MD/DO-275 waiver was associated with a 2.6% (95%CI: 1.1-4.1%) and 5.8% (4.1-7.4%) increase in buprenorphine prescribing among nonmetropolitan counties, respectively. Each additional MD/DO-275 waiver was associated with a 2.8% (1.0%-4.6%) increase in buprenorphine among metropolitan counties. There were no statistically significant associations between NP/PA waivers and buprenorphine prescribing among metropolitan counties or among either waiver type and opioid-related health outcomes. NP/PA waivers were associated with increased buprenorphine prescribing among nonmetropolitan counties and MD/DO-275 waivers were associated with increased buprenorphine prescribing among both metropolitan and nonmetropolitan counties.
Identifiants
pubmed: 34098203
pii: S0740-5472(21)00178-1
doi: 10.1016/j.jsat.2021.108452
pmc: PMC10023135
mid: NIHMS1876768
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Buprenorphine
40D3SCR4GZ
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
108452Subventions
Organisme : NIDA NIH HHS
ID : F31 DA047770
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA042720
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Addiction. 2019 Mar;114(3):471-482
pubmed: 30194876
Ann Fam Med. 2015 Jan-Feb;13(1):23-6
pubmed: 25583888
Addict Behav. 2007 Jul;32(7):1331-46
pubmed: 17092656
Psychol Addict Behav. 2011 Jun;25(2):215-24
pubmed: 21480679
JAMA Netw Open. 2018 Sep 7;1(5):e182943
pubmed: 30646185
J Opioid Manag. 2019 Sep/Oct;15(5):428-432
pubmed: 31849033
Health Serv Res. 2020 Jun;55(3):383-392
pubmed: 32166761
Drug Alcohol Depend. 2019 Nov 1;204:107527
pubmed: 31525570
Med Care. 2017 Nov;55(11):918-923
pubmed: 28930890
JAMA Netw Open. 2018 Aug 3;1(4):e181588
pubmed: 30646116
J Stud Alcohol Drugs. 2015 Jul;76(4):644-54
pubmed: 26098042
Subst Abus. 2020;41(2):259-268
pubmed: 31295057
Addiction. 2020 Sep;115(9):1683-1694
pubmed: 32096302
Drug Alcohol Depend. 2016 Dec 01;169:117-127
pubmed: 27810654
J Gen Intern Med. 2007 Sep;22(9):1325-9
pubmed: 17619934
Subst Abus. 2006 Sep;27(3):39-45
pubmed: 17135179
JAMA. 2019 Apr 9;321(14):1407-1408
pubmed: 30964519
Am J Psychiatry. 2020 Feb 1;177(2):117-124
pubmed: 31786933
JAMA. 2015 Oct 13;314(14):1515-7
pubmed: 26462001
Drug Alcohol Depend. 2013 Jul 1;131(1-2):23-35
pubmed: 23490450
Harv Rev Psychiatry. 2015 Mar-Apr;23(2):63-75
pubmed: 25747920
Health Aff (Millwood). 2020 May;39(5):747-755
pubmed: 32364847
Am J Public Health. 2019 Dec;109(12):1678-1679
pubmed: 31693402
Am J Addict. 2013 May-Jun;22(3):184-7
pubmed: 23617857
Int J Drug Policy. 2019 Nov;73:42-48
pubmed: 31336293
J Health Soc Behav. 1997 Jun;38(2):177-90
pubmed: 9212538
JAMA Psychiatry. 2016 Sep 1;73(9):990-2
pubmed: 27438334
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD002209
pubmed: 19588333
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
JAMA. 2020 Jan 21;323(3):276-277
pubmed: 31961408
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
J Addict Dis. 2006;25(4):91-103
pubmed: 17088229
JAMA Psychiatry. 2014 Apr;71(4):359-60
pubmed: 24500040
JAMA. 2019 Oct 1;322(13):1310-1312
pubmed: 31573628
J Subst Abuse Treat. 2009 Apr;36(3):244-51
pubmed: 18715741
J Rural Health. 2019 Jan;35(1):108-112
pubmed: 29923637
BMJ. 2017 Apr 26;357:j1550
pubmed: 28446428
Rural Remote Health. 2015;15:3019
pubmed: 25651434
Int J Drug Policy. 2017 Aug;46:172-179
pubmed: 28687187
Ann Fam Med. 2014 Mar-Apr;12(2):128-33
pubmed: 24615308
J Subst Abuse Treat. 2010 Sep;39(2):96-104
pubmed: 20598829
Cochrane Database Syst Rev. 2014 Feb 06;(2):CD002207
pubmed: 24500948
J Gen Intern Med. 2009 Feb;24(2):218-25
pubmed: 19089500
Transcult Psychiatry. 2016 Aug;53(4):465-87
pubmed: 27488225
Fam Med. 2006 May;38(5):336-40
pubmed: 16673195
J Opioid Manag. 2012 Jan-Feb;8(1):29-38
pubmed: 22479882
BMJ. 2020 Mar 31;368:m772
pubmed: 32234712
Health Aff (Millwood). 2019 Dec;38(12):2048-2056
pubmed: 31794302
Med Care Res Rev. 2020 Apr;77(2):208-216
pubmed: 30089426
JAMA Psychiatry. 2019 Mar 1;76(3):229-230
pubmed: 30586140
Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242
pubmed: 29779547
Am J Public Health. 2013 May;103(5):917-22
pubmed: 23488511